individualized anti-neoantigen hybrid TIL-TCR therapy (Neogene Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameindividualized anti-neoantigen hybrid TIL-TCR therapy (Neogene Therapeutics)
Drug Alias Nameindividualized anti-neoantigen TCR T cell therapy (Neogene Therapeutics)NT-125 (Neogene)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeogene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeogene Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A